Achyut Healthcare Ltd Q3 FY26 – ₹1.57 Cr Sales, Zero PAT, ₹132 Cr Market Cap: Pharma Hai Ya PowerPoint?
1. At a Glance – Blink and You’ll Miss the Profits
Achyut Healthcare Ltd is that one ₹132 Cr market cap pharma SME that looks like it should be doing something big… but mostly seems busy rearranging its share capital furniture. Current price? ₹5.59. Three-month return? -5.7%. One-year return? +37.7% (because microcaps love drama).
Latest quarterly sales clocked in at ₹1.57 Cr, while PAT politely chose to remain ₹0.00 Cr, like a guest who attends the wedding but skips the dinner. ROCE sits at 2.26%, ROE at 1.77%, and debt is technically zero — which is impressive, but also easy when operations are… let’s say minimalist.
Promoters hold 47.7%, FIIs have recently appeared with ~5.3%, and the company trades at 4.21× book value despite generating returns that wouldn’t impress a fixed deposit.
So the real question: Is this a hidden pharma turnaround… or just a very well-dressed balance sheet?
2. Introduction – Welcome to the Microcap Pharma Twilight Zone
Founded in 1996, Achyut Healthcare Ltd has survived three decades, multiple name changes, IPO excitement, bonus issues, preferential allotments, and now a migration dream from SME to mainboard. That alone deserves a slow clap 👏.
Officially, Achyut is into pharmaceutical formulations and trading — tablets, capsules, injectables, APIs, medical devices, and basically anything that can be written in a product list without needing a manufacturing plant photo.
But here’s where things get spicy.
Despite being in pharma — a sector where even mediocre players manage double-digit ROCE during good cycles — Achyut’s financials look like they’re running on homeopathic doses of scale. Revenues jump, fall, vanish, reappear, and profits depend more on other income than core operations in several years.
Yet, the stock has delivered 67.5% returns over three years. Why? Because in Indian markets, hope + corporate actions + low float = rocket fuel 🚀.
Let’s dissect whether there’s actual medicine inside this capsule, or just gelatin.
3. Business Model – WTF Do They Even Do?
On paper, Achyut Healthcare does two things:
Manufacturing pharmaceutical formulations
Trading APIs, formulations, and medical products
In reality, revenue numbers suggest the company is far more trader than manufacturer.
The product list is long enough to give an auditor neck pain:
Immunosuppressants like Tacrolimus, Sirolimus
APIs like Escitalopram, Diltiazem
COVID-era stars like Favipiravir
Even infrared thermometers (because why not?)
This tells us one thing clearly: 👉 Achyut is opportunistic, not specialised.
No single product dominance. No visible brand pull. No disclosed capacity utilisation.
It’s a “jo mile, woh becho” model — flexible, low capex, but brutally competitive and low-margin.
Ask yourself: In a pharma market dominated by Sun, Cipla, Divi’s and Lupin, what moat does a ₹3–6 Cr revenue company really have?
Exactly.
4. Financials Overview – Numbers That Whisper, Not Shout
📊 Quarterly Comparison Table (₹ Cr)
Source table
Metric
Latest Qtr (Dec-25)
YoY Qtr
Prev Qtr
YoY %
QoQ %
Revenue
1.57
0.00
2.55
NA
-38.4%
EBITDA
-0.01
-0.13
0.08
NA
-112%
PAT
0.00
0.03
0.12
-100%
-100%
EPS (₹)
0.00
0.00
0.01
NA
-100%
Annualised EPS (Q3 rule) Average EPS of Q1+Q2+Q3 ≈ effectively near zero → Annualised EPS ≈ ~₹0.00–0.01
So yes, P/E is meaningless here. Anyone quoting a P/E for Achyut is either brave or bored.
💬 Does this look like a company ready for a valuation rerating… or just surviving
